Deconditioning does not explain orthostatic intolerance in ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome)

C. (Linda) M. C. van Campen1*, Peter C. Rowe2 and Frans C. Visser1

Abstract
Background: Orthostatic intolerance (OI) is a frequent finding in individuals with myalgic encephalomyelitis /chronic fatigue syndrome (ME/CFS). Published studies have proposed that deconditioning is an important pathophysiological mechanism in various forms of OI, including postural orthostatic tachycardia syndrome (POTS), however conflicting opinions exist. Deconditioning can be classified objectively using the predicted peak oxygen consumption (VO2) values from cardiopulmonary exercise testing (CPET). Therefore, if deconditioning is an important contributor to OI symptomatology, one would expect a relation between the degree of reduction in peak VO2 during CPET and the degree of reduction in CBF during head-up tilt testing (HUT).

Methods and results: In 22 healthy controls and 199 ME/CFS patients were included. Deconditioning was classified by the CPET response as follows: %peak VO2 ≥ 85% = no deconditioning, %peak VO2 65–85% = mild deconditioning, and %peak VO2 < 65% = severe deconditioning. HC had higher oxygen consumption at the ventilatory threshold and at peak exercise as compared to ME/CFS patients (p ranging between 0.001 and < 0.0001). Although ME/CFS patients had significantly greater CBF reduction than HC (p < 0.0001), there were no differences in CBF reduction among ME/CFS patients with no, mild, or severe deconditioning. We classified the hemodynamic response to HUT into three categories: those with a normal heart rate and blood pressure response, postural orthostatic tachycardia syndrome, or orthostatic hypotension. No difference in the degree of CBF reduction was shown in those three groups.

Conclusion: This study shows that in ME/CFS patients orthostatic intolerance is not caused by deconditioning as defined on cardiopulmonary exercise testing. An abnormal high decline in cerebral blood flow during orthostatic stress was present in all ME/CFS patients regardless of their %peak VO2 results on cardiopulmonary exercise testing.

Keywords: Chronic fatigue syndrome, Myalgic encephalomyelitis, Peak oxygen consumption, Cardiopulmonary exercise test, Deconditioning, Cerebral blood flow, POTS, Orthostatic hypotension, Orthostatic intolerance, Head-up tilt testing

Introduction
Orthostatic intolerance (OI) is a frequent finding in individuals with myalgic encephalomyelitis /chronic fatigue syndrome (ME/CFS). The prevalence of OI symptoms in adults with ME/CFS varies between 28 and 96% in published studies [1]. This large variation is due to differences in patient selection, methodology of orthostatic testing and the comprehensiveness of ascertainment of orthostatic symptoms. In recent studies we found a prevalence of OI symptoms of 82% in adults and 96% in adolescents [2, 3]. OI is now considered one of the cardinal features of ME/CFS [1].

Some authors have proposed that deconditioning is an important pathophysiological mechanism in various...
forms of OI, including postural orthostatic tachycardia syndrome (POTS) [4–10]. In contrast, the 2015 Heart Rhythm Society Expert Consensus document on POTS states: “it is unclear whether deconditioning is the primary cause or a secondary phenomenon” [11].

Parsaik et al. suggested that the degree of deconditioning can be demonstrated by cardiopulmonary exercise testing (CPET) in patients with OI. The authors defined a percentage peak oxygen consumption (VO₂) cut-off value of ≥85% as indicating the absence of deconditioning, 65–84% as mild deconditioning, and <65% as severe deconditioning [6].

We recently reported that extracranial Doppler imaging of the internal carotid and vertebral arteries can measure the total cerebral blood flow (CBF) during head-up tilt testing (HUT), and thereby provides an objective confirmation of OI. In healthy adults, this technique identified a mean 7% reduction in CBF during a 30 min HUT. In ME/CFS patients however, the mean reduction in CBF was 26% [3]. Moreover, there was a significant relation between the CBF reduction and OI symptomatology during the tilt test. These data suggest that CBF measurements are more sensitive for OI in ME/CFS patients during HUT than the standard methods of classifying OI based on heart rates and blood pressures alone.

If deconditioning is an important contributor to OI symptomatology, then a relation between the degree of reduction in peak VO₂ during CPET and the reduction in CBF during HUT is to be expected. To investigate this hypothesis we examined all ME/CFS patients who had undergone both a CPET and CBF measurements during HUT.

Patients, material and methods
This was a retrospective study of patients referred between October 2012 and August 2020 to the Stichting CardioZorg, a cardiology clinic that specializes in the assessment and treatment of those with CFS and ME. All eligible participants had been referred by their general practitioners for the diagnosis of ME/CFS. Patients underwent a detailed clinical history, physical examination, laboratory analysis, ECG and echocardiography. Based on their symptoms, we established the diagnosis of chronic fatigue syndrome (CFS) according to the Fukuda Criteria [12] and myalgic encephalomyelitis (ME) according to the international ME criteria [13]. In all patients, alternative diagnoses which could explain the fatigue and other symptoms were ruled out.

From the entire referred population, patients were selected for this study if the HUT and a CPET were available and performed within a 1 year interval. HUT was performed because of the clinical suspicion of OI. CPET was performed for a variety of reasons: assessment of the heart rate (HR) at the ventilatory threshold (VT), to guide exercise activity [14, 15], to demonstrate reduction of the exercise capacity on day two of a 2-day CPET protocol [16–18], and to assess the degree of disability for social security claims.

This time interval of 1 year was intended to ensure that the clinical condition of the patient was relatively stable. Additionally, ME/CFS patients were selected with a proven significant CBF reduction (see below). For comparison, healthy controls (HC) who also underwent HUT and CPET within an interval of 3 month, were included. We excluded patients with a body mass index (BMI) of ≥37 [19], with an insufficient quality of the Doppler investigation, and if patients were using medications that lowered heart rate or blood pressure.

The changes in HR and blood pressure (BP) during head-up tilt test were classified according to the consensus statements [11, 20, 21]: normal HR and BP response, classic orthostatic hypotension (cOH; a decrease of over 20 mmHg in systolic blood pressure (SBP) and over 30 mmHg in the event of a SBP over 160 mmHg [22], or a decrease of 10 mmHg in diastolic blood pressure (DBP) from 1 to 3 min after onset of the tilt), delayed orthostatic hypotension (dOH; similar changes in BP as for classic orthostatic hypotension but developing after 3 min after onset of tilt), POTS (a sustained increase of at least 30 bpm within 10 min of tilting, without a significant decrease in BP), and syncope or near-syncope (VVS).

The study was carried out in accordance with the Declaration of Helsinki. All ME/CFS participants and HC gave informed, written consent authorizing us to use their medical records for research purposes. The study of the use of clinical data was approved by the medical ethics committee of the Slotervaart Hospital, number P1736, Amsterdam, NL. The testing of HC was approved by the same ethics committee, number P1411.

Head-up tilt test with cerebral blood flow measurements
Measurements were performed as described previously [23]. Briefly, all participants were positioned for 20 min in a supine position before being tilted head-up to 70 degrees for a maximum of 30 min. HR, SBP and DBP were continuously recorded by finger plethysmography using the Nexfin device (BMeye, Amsterdam, NL) [24, 25]. After the test, HR and BP’s were extracted from the Nexfin device and imported into an Excel spreadsheet. Internal carotid artery (ICA) and vertebral artery (VA) Doppler flow velocity frames were acquired by one operator in the supine position and twice during the upright phase, using a Vivid-I system (GE Healthcare, Hoevelaken, NL) equipped with a 6–13 MHz linear transducer. High resolution B mode images, color Doppler images, and the Doppler velocity spectrum (pulsed wave mode)
were recorded in one frame. At least two consecutive series of six cardiac cycles per artery were recorded.

Calculations of blood flow were performed as described previously [23] by another operator, unaware of the clinical data. In one cardiac cycle CBF was calculated from the mean blood flow velocity x the mean surface area. To compensate for respiratory variation, flow in the four arteries was calculated in 6 cardiac cycles and data were averaged. Total cerebral blood flow was calculated by adding the flow of the four arteries. For the present study the supine CBF and the CBF at the end of the upright phase of the HUT were taken. The end tilt CBF measurement was expressed as the percent reduction compared to the supine CBF. Because CBF Doppler measurements required approximately 3 min, we excluded those with rapid development of cOH and VVS because it was impossible to completely assess the 4 cerebral arteries while blood pressure was dropping rapidly. As cerebral blood flow is age dependent, differences between supine and end-tilt are shown as a percent reduction to enable comparison of ME/CFS patients with a broad age range [26–29]. Based on our previous study, we considered OI to be confirmed by CBF measurements if a reduction greater than 2 SD beyond the mean of the healthy volunteers [30]. This defines an abnormal CBF result as a >13% reduction during tilt.

Cardiopulmonary exercise testing
Patients underwent a symptom-limited exercise test on a cycle ergometer (Excalibur, Lode, Groningen, The Netherlands) according to a previously described protocol [31]. Briefly, a ramp workload protocol was used, varying between 10–30 W/min. Oxygen consumption (VO₂ in ml/min/kg), carbon dioxide release (VCO₂ in ml/min/kg), and oxygen saturation were continuously measured (Cortex, Procare, The Netherlands), and displayed on screen using Metasoft software (Cortex, Biophysic Gmbh, Germany). An ECG was continuously recorded and HR and BP were measured using the Nexfin device (BMEYE, Amsterdam, The Netherlands) [25]. The metabolic measurement system (Cortex, Biophysic Gmbh, Germany) was calibrated before each test with ambient air, standard gases of known concentrations, and a 3-L calibration syringe. The VT, a measure of the anaerobic threshold, was identified from expired gases using the V-Slope algorithm [32]. An experienced cardiologist supervised the test and performed visual assessment and confirmation of the algorithm-derived VT. The peak VO₂ was defined as the mean of the VO₂ measurements of the last 15 s before ending the exercise. VO₂ at the VT and peak were expressed as a percentage of the normal values of a population study: %VT VO₂, %peak VO₂ [19]. Also, the mean respiratory exchange ratio (RER; VCO₂/VO₂) of the last 15 s was calculated [33]. As absolute oxygen consumption differs between males and females and are age related results are shown in percent of a reference group to enable comparison of both genders and a broad age range [34–39].

Statistical analysis
Data were analyzed using Graphpad Prism version 8.2.4 (Graphpad software, La Jolla, California, USA). All continuous data were tested for normal distribution using the D’Agostino & Pearson omnibus normality test, and presented as mean (SD) or as median (IQR), where appropriate. Nominal data (gender, hemodynamic tilt test results, oxygen consumption: normal, moderate deconditioning, and severe deconditioning) were compared using the Chi-square test (up to a 3 × 3 table). For continuous data, groups were compared using the paired or unpaired t-test or with a Wilcoxon matched-pairs signed rank test or Mann–Whitney test where appropriate. Within group comparison was performed using the ordinary one-way analysis of variance (ANOVA) or Kruskal–Wallis test where appropriate. Where significant, results were then explored further using the post-hoc Tukey’s test or Dunn’s test where appropriate. Within-group comparison was performed using the two-way ANOVA. Where significant, results were then explored further using the post-hoc Holm-Sidak test. Linear regression was performed to assess the relation between measures (percent CBF reduction from supine to end-tilt and percent peak VO₂ for all patients shown for different hemodynamic results on HUT as POTS etc., HC as a group and results split in time intervals). We elected to use a more conservative p-value of <0.01 to indicate statistical significance.

Results
Participants
Between October 2012 and August 2020, 1124 patients met the criteria for ME/CFS. In 916 patients a HUT was performed because of the clinical suspicion of OI. Of those 916 patients 65 patients were excluded because of insufficient quality or missing data of the CBF measurements, the presence of cOH and VVS, or the use of HR and BP lowering drugs. Of the remaining 851 patients, 249 underwent at least one cardiopulmonary exercise test. Of those 249, two were excluded due to HR and BP lowering medication use, none because of a BMI ≥ 37. In 199 patients the interval between the HUT and CPET was less than 1 year (mean interval 4 ± 3 month) and in 48 patients the interval was more than 1 year. Review of the patient charts showed that none of the 199 patients had a major change in symptoms or function due to an adverse event like surgery, trauma, or a serious infection.
like EBV. Twenty-eight subjects of the group with a normal HR and BP (normHRBP) response during HUT (21%) showed a normal CBF reduction, while the remaining 105 (79%) showed an abnormal CBF reduction. All patients with POTS (n = 39) and dOH (n = 27) showed an abnormal CBF reduction, leading to a total of 171 patients to be studied. In 67 patients, HUT was performed after the CPET, in 106 patients HUT was performed before the CPET. There were no differences in demographic data between ME/CFS patients who were included or excluded from the study (data not shown). Twenty-two HC fulfilled the inclusion criteria of undergoing a HUT and CPET within the fixed study interval of one year and had a normal HR and BP response during HUT. None of them used medication except for the occasional use of pain medication. The data of HC and patients with a normal HR and BP response and a normal CBF reduction are provided in Additional file 1 data section.

Table 1 shows the demographic data of the ME/CFS patients with a normal HR and BP response (n = 105), POTS (n = 39), and dOH (n = 27). Demographics did not differ significantly between the three groups.

Table 2 shows the results of the CPET in the three ME/CFS groups. None of the studied parameters differed between the three groups. Table 3 shows the hemodynamic and CBF data during HUT of the three patient groups. By definition, end-tilt HR was highest in the POTS patient group compared the other two patient groups (both p < 0.0001). By definition, end-tilt SBP in patients with dOH was lower compared to the other two patient groups but only reached significance in the comparison of dOH patients vs the normHRBP patients: p < 0.0001. Similarly, end-tilt DBP was lower in the dOH group.

### Table 1
Demographic data of ME/CFS patients with a normal HR and BP response (group 1), ME/CFS patients with POTS (group 2), and ME/CFS patients with dOH (group 3), all with a significant CBF decrease as measured during HUT

| Group 1: NormHRBP (n = 105) | Group 2: POTS (n = 39) | Group 3: dOH (n = 27) | Ordinary one-way ANOVA with post hoc Tukey's test |
|-----------------------------|-----------------------|-----------------------|-------------------------------------------------|
| Male/female                 | 21/84                 | 10/29                 | 5/22                                             |
| Age (years)                 | 41 (9)                | 38 (11)               | 43 (12)                                          |
| Height (cm)                 | 171 (8)               | 175 (10)              | 173 (9)                                          |
| Weight (kg)                 | 73 (16)               | 75 (14)               | 73 (14)                                          |
| BMI (kg/m²)                 | 24.9 (4.8)            | 24.6 (3.8)            | 24.5 (5.3)                                       |
| BSA (m²)                    | 1.85 (0.20)           | 1.90 (0.21)           | 1.86 (0.17)                                      |
| Disease duration (yrs)      | 11 (5–16.5)           | 7 (4–13)              | 11 (4–18)                                        |

BMI body mass index, BSA body surface area (formula DuBois), Dis duration disease duration, NormHRBP normal heart rate and blood pressure response during HUT, dOH delayed orthostatic hypotension during HUT, POTS postural orthostatic tachycardia syndrome during HUT, yrs years given as median with IQR

### Table 2
CPET data in ME/CFS patients with a normal HR/BP response (group 1), ME/CFS patients with POTS (group 2), and ME/CFS patients with dOH (group 3), all with a significant CBF decrease as measured during HUT

| CPET data          | Group 1: NormHRBP (n = 105) | Group 2: POTS (n = 39) | Group 3: dOH (n = 27) | Ordinary one-way ANOVA with post hoc Tukey's test |
|--------------------|------------------------------|------------------------|-----------------------|-------------------------------------------------|
| HR rest (bpm)      | 86 (14)                      | 86 (12)                | 86 (15)               | F (2, 168) = 0.02; p = 0.98                      |
| HR peak (bpm)      | 147 (23)                     | 146 (19)               | 146 (25)              | F (2, 168) = 0.03; p = 0.97                      |
| SBP rest (mmHg)    | 125 (16)                     | 120 (14)               | 128 (15)              | F (2, 168) = 1.25; p = 0.29                      |
| DBP rest (mmHg)    | 84 (10)                      | 81 (11)                | 83 (12)               | F (2, 168) = 0.67; p = 0.52                      |
| SBP peak (mmHg)    | 165 (26)                     | 158 (26)               | 161 (26)              | F (2, 168) = 0.79; p = 0.46                      |
| DBP peak (mmHg)    | 99 (13)                      | 92 (13)                | 96 (12)               | F (2, 168) = 2.36; p = 0.10                      |
| VT VO₂ (ml/min/kg) | 12 (4)                       | 11 (3)                 | 12 (4)                | F (2, 168) = 1.28; p = 0.28                      |
| Peak VO₂ (ml/min/kg)| 21 (7)                      | 19 (5)                 | 21 (7)                | F (2, 168) = 0.80; p = 0.45                      |
| %VT VO₂            | 41 (11)                      | 36 (11)                | 41 (12)               | F (2, 168) = 2.81; p = 0.06                      |
| %peak VO₂          | 70 (21)                      | 62 (16)                | 71 (21)               | F (2, 168) = 2.59; p = 0.08                      |
| RER                | 1.06 (0.12)                  | 1.11 (0.12)            | 1.09 (0.12)           | F (2, 168) = 2.12; p = 0.12                      |

DBP diastolic blood pressure, dOH delayed orthostatic hypotension during HUT, HR heart rate, NormHRBP normal heart rate and blood pressure response during HUT, POTS postural orthostatic tachycardia syndrome during HUT, RER respiratory exchange ratio, SBP systolic blood pressure, VO₂ oxygen consumption in ml/min/kg, VT ventilatory threshold, % VO₂ oxygen consumption as percentage of normal values of a population study (19)

* A p-value of < 0.01 was considered significantly different for this study
patients compared to the other two patient groups, but only reached significance in the comparison of dOH patients vs the normHRBP patients: p < 0.0001. Baseline, end tilt CBF, and the %CBF reduction were not different between the three patient groups.

Figure 1 shows the regression analysis of the relation between %peak VO$_2$ during CPET and the CBF change during HUT in all three groups. In none of the three groups did the slope of the regression line differ from zero, indicating absence of relationship between exercise performance/deconditioning and orthostatic intolerance. Moreover, the slope of the regression lines did not differ between the three groups.

Among ME/CFS patients, Table 4 shows the distribution of deconditioning as determined with the CPET (no deconditioning = peak VO$_2$ ≥ 85%, mild deconditioning = peak VO$_2$ 65–85%, and severe deconditioning = peak VO$_2$ < 65%) [6] across the different hemodynamic responses during HUT. No significant differences in distribution were found (p = 0.32).

Figure 2 displays the degree of CBF reduction in the three ME/CFS patient groups when subdivided according to the degree of deconditioning. In none of the three patient groups was there a significant difference in the degree of CBF reduction across the three categories of deconditioning.

Figure 3 shows the subgroup analysis of patients in whom the interval between HUT and CPET was less than 4 month, in whom the interval was between 4 and 8 month and in whom the interval was between 8 month and 1 year. No difference in the relation between %peak VO$_2$ and the CBF reduction was found. None of the three slopes was different from zero. Moreover, the mean %peak VO$_2$ did not differ between groups nor did the percent CBF reduction (data not shown).

**Table 3** Hemodynamic data during HUT in ME/CFS patients with a normal HRBP response (group 1), with POTS (group 2) and with dOH (group 3), all with a significant CBF decrease as measured during HUT

| HUT data | Group 1 (n = 105) | Group 2 (n = 39) | Group 3 (n = 27) | Ordinary one-way ANOVA with post hoc Tukey’s test |
|----------|-------------------|-----------------|-----------------|-----------------------------------------------|
| HR supine (bpm) | 73 (11) | 77 (14) | 73 (10) | F (2, 168) = 1.83; p = 0.16 |
| HR end tilt (bpm) | 90 (14) | 114 (24) | 90 (16) | F (2, 168) = 29.52; p < 0.0001; 1 vs 2 p < 0.0001; 1 vs 3 p = 0.99; 2 vs 3 p < 0.0001 |
| SBP supine (mmHg) | 134 (15) | 132 (16) | 142 (19) | F (2, 168) = 3.14; p = 0.04# |
| SBP end tilt (mmHg) | 131 (16) | 119 (24) | 109 (16) | F (2, 168) = 19.14; p < 0.0001; 1 vs 2 p = 0.0088; 1 vs 3 p < 0.0001; 2 vs 3 p = 0.09 |
| DBP supine (mmHg) | 79 (8) | 78 (8) | 81 (9) | F (2, 168) = 1.21; p = 0.30 |
| DBP end tilt (mmHg) | 84 (9) | 81 (16) | 72 (13) | F (2, 168) = 10.91; p < 0.0001; 1 vs 2 p = 0.25; 1 vs 3 p < 0.0001; 2 vs 3 p = 0.01# |
| CBF supine (ml/min) | 628 (107) | 608 (96) | 611 (98) | F (2, 168) = 1.29; p = 0.30 |
| CBF end tilt (ml/min) | 456 (83) | 435 (79) | 435 (79) | F (2, 168) = 0.70; p = 0.50 |
| %CBF reduction | − 27.4 (6.1) | − 28.6 (5.3) | − 28.8 (4.9) | F (2, 168) = 0.98; p = 0.38 |

CBF cerebral blood flow, DBP diastolic blood pressure, dOH delayed orthostatic hypotension during HUT, HR heart rate, HUT head-up tilt test, NormHRBP normal heart rate and blood pressure response during HUT, POTS postural orthostatic tachycardia syndrome during HUT, SBP systolic blood pressure

* A p-value of < 0.01 was considered significantly different for this study

**Fig. 1** Correlation between the percent CBF reduction at end-tilt compared to supine and the percentage peak VO$_2$ for all ME/CFS patients (n = 199 and HC (n = 22). CBF cerebral blood flow in ml/min/kg, dOH delayed orthostatic hypotension, HC healthy controls, normHRBP normal heart rate and blood pressure response during HUT, POTS postural orthostatic tachycardia syndrome, percent VO$_2$ oxygen consumption as percentage of normal values of a population study [19]. The insert figure above right shows the linear regression analysis of HC and norm HRBP patients with a normal CBF (OI-) reduction during HUT: see Additional file 1.
abnormal reduction in CBF during tilt, consistent with orthostatic intolerance. All patients with POTS (n = 39), all with dOH (n = 27), and 105/133 (79%) of those with a normal HR and BP response had a greater than 13% CBF reduction during tilt. In the three groups of patients with an abnormal CBF reduction during HUT there was no relation between the percent peak VO₂ and the CBF reduction during HUT (see Fig. 1). Also, when categorizing the percent peak VO₂ as no deconditioning, mild, and severe deconditioning [6], no significant differences were found in the three patient categories based on HUT HR and BP results (see Fig. 2). In the group of ME/CFS patients (n = 28) without the presence of clinical manifestation of OI, the same range in peak VO₂ results was found (Additional file 1: Fig. S2) in comparison to ME/CFS patients with the presence of clinical manifestation of OI (CBF > 13%). Taken together, these findings provide

Table 4 Distribution of the degree of deconditioning according Parsaik and colleagues across ME/CFS hemodynamic groups (normal HR/BP response, POTS, and dOH), all with a significant CBF decrease as measured during HUT

| Degree deconditioning* | NormHRBP (n = 105) | POTS (n = 39) (%) | dOH (n = 27) (%) | Total |
|------------------------|--------------------|-------------------|------------------|-------|
| No deconditioning: %peak VO₂ ≥ 85% (n =) | 27 (26%) | 4 (11%) | 7 (26%) | 38 |
| Mild deconditioning %peak VO₂ 65–85% (n =) | 33 (31%) | 13 (33%) | 7 (26%) | 53 |
| Severe deconditioning: %peak VO₂ < 65%(n =) | 45 (43%) | 22 (56%) | 13 (48%) | 80 |
| Total | 105 | 39 | 27 | 171 |

Chi square statistics = 5.41(p = 0.25)(3 × 3 table)

dOH delayed orthostatic hypotension during HUT, NormHRBP normal heart rate and blood pressure response during HUT, POTS postural orthostatic tachycardia syndrome during HUT, %peak VO₂ oxygen consumption as percentage of normal values of a population study [19]

* Subgrouping of the degree of deconditioning according to Parsaik et al. [6]
exercise performance/peak VO2 in ME/CFS patients

ME/CFS patients a positive correlation between the hand peripheral autonomic neuropathy [55, 57–61], high ever, alternative explanations for POTS include blood deconditioning in a number of studies [6–8, 54], and emphasized in POTS patients. POTS has been related namic abnormalities obtained by HUT has mainly been deconditioning and muscle bulk is the most important and consistently reported fe-

ure of deconditioning. Reduced peak VO2 and decreased cardiac output during exercise are also linked to deconditioning but may primarily result from the reduction in muscle bulk. Muscle strength has been studied in ME/ CFS patients using the hand grip strength test, showing reduced hand grip strength compared to healthy controls and MS patients [49]. Nevertheless, measuring exercise capacity/peak VO2 is considered to be the gold standard for assessing deconditioning [6]. In a recent meta-analysis Franklin and coworkers reviewed the available literature on peak VO2 in ME/CFS patients versus HC [50]. The authors concluded that despite substantial between-study variability, the available evidence indicates that ME/CFS patients have a significantly lower peak VO2 compared to HC. One recent study found in ME/CFS patients a positive correlation between the hand grip strength and peak VO2 [51]. The causes of a reduced exercise performance/peak VO2 in ME/CFS patients involve both skeletal muscle fatigue and an altered central nervous system innervation (reviewed by Jammes and Retornaz [52]). Moreover, chronotropic incompetence during exercise in ME/CFS patients [53], and cardiovascular deconditioning [41] have also been shown to contribute to the VO2 reduction. The relation between deconditioning and hemodynamic abnormalities obtained by HUT has mainly been emphasized in POTS patients. POTS has been related to deconditioning in a number of studies [6–8, 54], and all these studies advocate exercise training as part of the treatment, implying that deconditioning is at least a contributor to the pathophysiology of POTS. However, alternative explanations for POTS include blood volume reduction [55], mast cell activation disorders [56], peripheral autonomic neuropathy [55, 57–61], high levels of norepinephrine while standing [62], and genetic abnormalities [63]. Importantly, in the present study 11% of the ME/CFS patients with POTS had no signs of deconditioning and 33% had mild deconditioning (see Table 4). Irrespective of the degree of deconditioning, all ME/CFS patients with POTS showed an abnormal CBF reduction during tilt table testing. If there had been a clear relationship between the degree of CBF reduction (objectively confirmed OI) and the degree of %peak VO2 reduction (objectively confirmed deconditioning), then this would have provided support for the hypothesis that exercise therapy would be beneficial for treating OI in ME/CFS. Instead, our data suggest instead that exercise therapy alone is unlikely to be effective in improving OI symptoms in this patient population, and that effective treatment of the orthostatic intolerance is more likely to lead to improved function. This holds true not only for ME/CFS patients with POTS, but also for ME/CFS patients with a normal HR and BP response and ME/CFS patients with dOH. As a clinical implication therefore, exercise therapy is not likely to solve the problem of OI, at least in patients with ME/CFS and should therefore be part of a treatment suggestion carefully. Other types of treatment might be more successful in improving patient symptomatology.

Reduced blood volume and abnormal venous pooling are present in POTS and also in other forms of orthostatic intolerance. In an earlier study of ME/CFS patients without POTS we confirmed the relation between blood volume reduction and increase in OI complaints and the relation between blood volume reduction and the reduction in %peak VO2 [64, 65]. Furthermore, we have also shown a larger cardiac index reduction during HUT in ME/CFS patients compared to healthy volunteers, supporting the pooling hypothesis [66].

Limitations
The patients included in this study were a subset of stable ME/CFS patients with a HUT and a CPET within a 1 year interval. Stability of disease was confirmed by review of patient charts by an experienced clinician. Furthermore HUT was performed in patients not on OI medication or using compression stockings. This may have introduced bias. The maximum interval between HUT and CPET was set at 1 year. However, the subgroup analysis of patients with an interval less than 4 month, between 4 and 8 month and between 8 month and 1 year showed no deviation from the main study findings using the entire sample, namely that there was no relation between the percent peak VO2 and CBF reduction. Nevertheless, prospective confirmation of our findings is needed. Our clinic evaluates patients suspected of having ME/CFS. We cannot comment on
whether our results in ME/CFS patients with POTS can be extended to those with POTS alone (without ME/CFS)—a group that typically has milder functional impairments—as we included no patients with POTS alone in our study. This question deserves attention in future studies.

Conclusion
In spite of the commonly held view that there is a causal relation between deconditioning and OI, this study provides no support for this hypothesis. In ME/CFS patients, the objective measure of OI as defined by CBF reduction during HUT was not related to deconditioning as defined by the %peak VO2 obtained during CPET.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-02819-0.

Additional file 1. Table S1. Baseline characteristics of HC and ME/CFS patients with a normal HR and BP response and a normal CBF reduction during HUT; Table S2. CPET results of HC and ME/CFS patients with a normal HR and BP response and a normal CBF reduction during HUT; Table S3. HUT results in healthy controls and ME/CFS patients with a normal HR and BP response and a normal CBF reduction during HUT; Figure S1. Flow diagram showing the flow of recruitment and patient flow explaining reasons for exclusion and number of patients analyzed; Figure S2. Correlation between the percent CBF reduction at end-tilt compared to supine and the percentage peak VO2 for HC (n=22) and for ME/CFS patients with a normal HR and BP response and a normal CBF reduction during HUT (n=28).

Acknowledgements
Dr. Rowe is supported by the Sunshine Natural Wellbeing Foundation Professorship of Chronic Fatigue and Related Disorders.

Authors’ contributions
CMCVC, PCR, and FCV conceived the study, CMCVC and FCV collected the data, CMCVC performed the primary data analysis and FCV and PCR performed secondary data analyses. All authors were involved in the drafting and review of the manuscript. All authors read and approved the final manuscript.

Funding
As stated before the introduction, this study/manuscript was not funded.

Data availability statement
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Declarations
Ethics approval and consent to participate
As already stated in the methodology section: “The study was carried out in accordance with the Declaration of Helsinki. All ME/CFS participants and HC gave informed, written consent authorizing us to use their medical records for research purposes. The study of the use of clinical data was approved by the medical ethics committee of the Slotervaart Hospital, number P1736, Amsterdam, NL. The testing of HC was approved by the same ethics committee, number P1411.”

Consent of publication
Not applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1. Stichting CardioZorg, Planetenweg 5, 2132 ZH Hoofddorp, Netherlands. 2. Department of Paediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 2 December 2020   Accepted: 8 April 2021
Published online: 04 May 2021

References
1. Institute Of Medicine (IOM), editor. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington DC: The National Academies Press; 2015.
2. Roma M, Marden CL, Flaherty MA, Jasen SE, Cranstion EM, Rowe PC. Impaired health-related quality of life in adolescent myalgic encephalomyelitis/chronic fatigue syndrome: the impact of core symptoms. Front Pediatr. 2019;7:26.
3. van Campen CLMC, Verheugt FWA, Rowe PC, Visser FC. Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: a quantitative, controlled study using Doppler echography. Clin Neurophysiol Pract. 2020;5:50–8.
4. Lee SM, Feiveson AH, Stein S, Stenger MB, Platts SH. Orthostatic intolerance after ISS and space shuttle missions. Aerosp Med Hum Perform. 2015;86(12 Suppl):A54-67.
5. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20(3):352–8.
6. Parsaik A, Allison TG, Singer W, Sletten DM, Joyner MJ, Benaroch EE, et al. Deconditioning in patients with orthostatic intolerance. Neurology. 2012;79(14):1435–9.
7. Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15(9):60.
8. Joyner MJ, Masaki S. POTS versus deconditioning: the same or different? Clin Auton Res. 2008;18(6):300–7.
9. Benaroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012;87(12):1244–25.
10. Shibata S, Fu Q, Bivens TB, Hastings JL, Wang W, Levine BD. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol. 2012;590(Pt 15):3495–505.
11. Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–63.
12. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–9.
13. Carruthers BM, van de Sande MJ, Meirleir KE, Klimas NGGT, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327–38.
14. van Campen CLMC, Rowe PC, Visser FC. Heart rate thresholds to limit activity in myalgic encephalomyelitis/chronic fatigue syndrome patients (Pacing): comparison of heart rate formulae and measurements of the heart rate at the lactic acidosis threshold during cardiopulmonary exercise testing. Adv Phys Educ. 2020;10(1):38–54.
15. Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T. Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. Phys Ther. 2010;90(4):602–14.
16. VanNess JM, Snell CR, Stevens SR. Diminished cardiopulmonary capacity during post-exertional malaise. J Chronic Fatigue Syndr. 2007;14:77–85.
17. van Campen CMC, Rowe PC, Visser FC. Two-day cardiopulmonary exercise testing in females with a severe grade of myalgic encephalomyelitis/chronic fatigue syndrome: comparison with patients with a mild and moderate disease. Healthcare. 2020;8(3):192.

18. van Campen CMC, Rowe PC, Visser FC. Validity of 2-day cardiopulmonary exercise testing in male patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv Phys Educ. 2020;10:68–80.

19. Glaser S, Koch B, Ittermann T, Schaper C, Dorr M, Felix SB, et al. Influence of age, sex, body size, smoking, and beta blockade on key gas exchange exercise parameters in an adult population. Eur J Cardiovasc Prev Rehabil. 2010;17(4):469–76.

20. Shen WK, Sheldon RS, Bennett DG, Cohen ML, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS guide for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017;70(5):520–63.

21. Freeman R, Weling W, Axelrod FB, Bennett DG, Benarrach E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161(1–2):46–8.

22. Fedorowski A, Burn P, Melander O. Orthostatic hypotension in genetically related hypotensive and normotensive individuals. J Hypertens. 2009;27(5):976–82.

23. van Campen CMC, Verheugt FWA, Visser FC. Cerebral blood flow changes during tilt table testing in healthy volunteers, as assessed by Doppler imaging of the carotid and vertebral arteries. Clin Neurophysiol Pract. 2018;3:91–5.

24. Eeftinck Schattenkerk DW, van Lieshout JJ, van den Meiracker AH, Wesseling KR, Blascz C, Weling W, et al. Noninvasive continuous arterial blood pressure validated against Riva-Rocci/Korotkoff. Am J Hypertens. 2009;22(4):378–83.

25. Martina JR, Westerhof BE, van Goudoever J, de Beaumont EM, Truijen J, et al. The contribution by body composition and haemoglobin concentrations with fatigue, impairment and physical activity. Psychol Med. 2001;31(1):107–14.

26. Inbar O, Dlin R, Rotstein A, Whipp BJ. Physiological responses to incremental exercise in patients with chronic fatigue syndrome. Med Sci Sports Exerc. 2001;33(9):1463–70.

27. Wallman KE, Morton AR, Goodman C, Grove R. Physiological responses during a submaximal cycle test in chronic fatigue syndrome. Med Sci Sports Exerc. 2004;36(10):1682–8.

28. Sargent C, Scoop GC, Nemeth PM, Burnet RB, Buckley JD. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome. Med Sci Sports Exerc. 2002;34(1):51–6.

29. Nacul LC, Mudie K, Kingdon CC, Clark TG, Lacerda EM. Hand grip strength as a clinical biomarker for ME/CFS and disease severity. Front Neurol. 2018;9:992.

30. Franklin JD, Atkinson G, Atkinson JM, Ratterman AM. Peak oxygen uptake in chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Int J Sports Med. 2019;40(2):77–87.

31. Jammes Y, Stavris C, Charpin C, Rebaudet S, Lagrange G, Retornaz F. Exercise capacity in chronic fatigue syndrome: aetiology and management. J Intern Med. 2019;285(4):352–66.

32. Raj SR, Biaggioni I, Yamhure PC, Byrne DW, De Meirleir K, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with postural tachycardia syndrome. J Am Coll Cardiol. 2017;70(1):1–36.

33. Halliwell SH, Black MR, De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352–66.

34. Raj SR, Biaggioni I, Yamhure PC, Black MR, Paranjape SY, Byrne DW, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005;111(3):1574–82.

35. Shibao C, Arzuabigia C, Roberts LJ 2nd, Raj S, Black B, Harris P, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385–90.

36. Grubb BP. Postural tachycardia syndrome. Circulation. 2008;117(21):2814–7.

37. Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasconstrictive but not venous compliance defects. Circulation. 2002;105(19):2274–81.

38. Sharma HB, Kaila8iya J. Gender difference in aerobic capacity and the contribution by body composition and haemoglobin concentration: A study in young indian national hockey players. J Clin Diagr Res. 2016;10(11):9–13.

39. Wheatley CM, Snyder EM, Johnson BD, Olson TP. Sex-related differences in the normal cardiac response to upright exercise. Circulation. 1984;70(3):357–66.

40. Verbeek JH, Bazelmans E, Swarnink CM, Penjis EF, Galama JM, Jongen PJ, et al. Physical activity in chronic fatigue syndrome: assessment and its role in fatigue. J Psychiatri Res. 1997;31(6):661–73.

41. De Lorenzo F, Xiong H, Mukherjee M, Harcup J, Suleiman S, Kadiola Z, et al. Chronic fatigue syndrome: physical and cardiovascular deconditioning. QJM. 1998;91(7):475–81.

42. Riley MS, O’Brien CJ, McCluskey DR, Bell NP, Nicholls DP. Aerobic work capacity in patients with chronic fatigue syndrome. BMJ. 1990;301(6758):953–6.

43. Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2000;69(3):502–7.

44. De Becker P, Roeykens J, Reynolds M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. Arch Intern Med. 2000;160(12):1270–7.

45. Bazelmans E, Bleijenberg G, van der Meer JW, Folgering H. Is physical deconditioning a perpetuating factor in chronic fatigue syndrome? A controlled study on maximal exercise performance and relations with fatigue, impairment and physical activity. Psychol Med. 2001;31(1):107–14.

46. Inbar O, Dlin R, Rotstein A, Whipp BJ. Physiological responses to incremental exercise in patients with chronic fatigue syndrome. Med Sci Sports Exerc. 2001;33(9):1463–70.

47. Wallman KE, Morton AR, Goodman C, Grove R. Physiological responses during a submaximal cycle test in chronic fatigue syndrome. Med Sci Sports Exerc. 2004;36(10):1682–8.

48. Sargent C, Scoop GC, Nemeth PM, Burnet RB, Buckley JD. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome. Med Sci Sports Exerc. 2002;34(1):51–6.

49. Nacul LC, Mudie K, Kingdon CC, Clark TG, Lacerda EM. Hand grip strength as a clinical biomarker for ME/CFS and disease severity. Front Neurol. 2018;9:992.

50. Franklin JD, Atkinson G, Atkinson JM, Ratterman AM. Peak oxygen uptake in chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Int J Sports Med. 2019;40(2):77–87.

51. Jammes Y, Stavris C, Charpin C, Rebaudet S, Lagrange G, Retornaz F. Exercise capacity in chronic fatigue syndrome: aetiology and management. J Intern Med. 2019;285(4):352–66.

52. Raj SR, Biaggioni I, Yamhure PC, Byrne DW, De Meirleir K. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352–66.

53. Raj SR, Biaggioni I, Yamhure PC, Black MR, Paranjape SY, Byrne DW, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005;111(3):1574–82.

54. Shibao C, Arzuabigia C, Roberts LJ 2nd, Raj S, Black B, Harris P, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385–90.

55. Grubb BP. Postural tachycardia syndrome. Circulation. 2008;117(21):2814–7.

56. Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasconstrictive but not venous compliance defects. Circulation. 2002;105(19):2274–81.
59. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993;43(1):132–7.

60. Streeten DH. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J Clin Invest. 1990;86(5):1582–8.

61. Hoeldtke RD, Davis KM. The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. J Clin Endocrinol Metab. 1991;73(1):132–9.

62. Mar PL, Raj SR. Neuronal and hormonal perturbations in postural tachycardia syndrome. Front Physiol. 2014;5:220.

63. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000;342(8):541–9.

64. van Campen CMC, Visser FC. Blood volume status in patients with chronic fatigue syndrome: relation to complaints. Int J Clin Med. 2018;9:809–19.

65. van Campen CMC, Rowe PC, Visser FC. Blood volume status in ME/CFS correlates with the presence or absence of orthostatic symptoms: preliminary results. Front Pediatr. 2018;6:4.

66. van Campen CMC, Visser FC. The abnormal Cardiac Index and Stroke Volume Index changes during a normal Tilt Table Test in ME/CFS patients compared to healthy volunteers, are not related to deconditioning. J Thrombos Circ. 2018;2:1–8.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.